Investigational Drug Information for Talarozole
✉ Email this page to a colleague
What is the drug development status for Talarozole?
Talarozole is an investigational drug.
There have been 4 clinical trials for Talarozole.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2006.
The most common disease conditions in clinical trials are Psoriasis, Inflammation, and Dermatitis. The leading clinical trial sponsors are Stiefel, a GSK Company, GlaxoSmithKline, and [disabled in preview].
Summary for Talarozole
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 73 |
| WIPO Patent Applications | 40 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 2 (2006-06-01) |
| Vendors | 55 |
Recent Clinical Trials for Talarozole
| Title | Sponsor | Phase |
|---|---|---|
| Study on Anti-inflammatory Effects of Topical R115866 Gel | Stiefel, a GSK Company | Phase 1 |
| Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis | GlaxoSmithKline | Phase 2 |
| Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis | Stiefel, a GSK Company | Phase 2 |
Clinical Trial Summary for Talarozole
Top disease conditions for Talarozole
Top clinical trial sponsors for Talarozole
US Patents for Talarozole
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
